Clearside Biomedical, Inc. - Common Stock, $0.001 par value (CLSD)

Historical Holders from Q2 2016 to Q3 2025

Type / Class
Equity / Common Stock, $0.001 par value
Symbol
CLSD on Nasdaq
Shares outstanding
76,991,404
Price per share
$3.97
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
114,849
Total reported value
$446,925
% of total 13F portfolios
0%
Share change
-9,177,966
Value change
-$11,767,256
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
3
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Clearside Biomedical, Inc. - Common Stock, $0.001 par value (CLSD) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WHITMORE BRADFORD T 8.6% $4,957,868 6,523,511 WHITMORE BRADFORD T 31 Dec 2024
Wiles Stephen Boyd 5.2% $3,042,700 4,003,553 Stephen Boyd Wiles 31 Mar 2025
As of 30 Sep 2025, Clearside Biomedical, Inc. - Common Stock, $0.001 par value (CLSD) has 3 institutional shareholders filing 13F forms. They hold 114,849 shares. of 76,991,404 outstanding shares (0.15%) .

Institutional Holders of Clearside Biomedical, Inc. - Common Stock, $0.001 par value (CLSD) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q3 114,849 $446,925 -$11,767,256 397% 3
2025 Q2 9,385,817 $7,508,386 +$449,380 80% 44
2025 Q1 8,812,320 $8,089,826 -$576,885 91.79% 44
2024 Q4 9,438,248 $8,967,558 -$10,833,385 95% 44
2024 Q3 10,051,240 $22,741,735 -$4,794,616 127% 49
2024 Q2 13,768,135 $17,898,695 -$2,355,972 130% 49
2024 Q1 15,525,337 $23,755,690 +$11,991,718 153% 53
2023 Q4 0 $0 -$71,767 0
2023 Q3 7,836,345 $6,816,694 -$748,272 86.99% 45
2023 Q2 8,593,115 $9,623,042 -$243,656 112% 53
2023 Q1 8,732,023 $9,080,104 -$468,292 104% 48
2022 Q4 9,119,584 $10,212,085 -$824,595 112% 51
2022 Q3 12,074,250 $13,642,782 -$1,773,039 112.99% 46
2022 Q2 13,686,914 $20,116,157 -$4,094,454 146.94% 47
2022 Q1 16,371,849 $37,492,487 -$12,563,225 229.03% 58
2021 Q4 21,007,920 $57,776,213 -$5,523,117 275.03% 63
2021 Q3 20,253,624 $121,519,006 +$4,442,680 600% 64
2021 Q2 19,662,301 $95,752,005 -$3,805,434 486.97% 53
2021 Q1 16,008,689 $39,542,002 +$8,496,785 247.02% 50
2020 Q4 12,567,908 $34,432,022 +$4,193,561 273.99% 38
2020 Q3 11,972,567 $18,436,012 -$33,772 153.93% 39
2020 Q2 11,780,473 $22,149,015 +$523,855 188.04% 43
2020 Q1 11,469,488 $19,499,099 +$5,913,228 170% 38
2019 Q4 7,942,384 $23,036,168 +$2,760,757 290% 44
2019 Q3 6,986,676 $4,403,981 +$1,247,989 63.02% 28
2019 Q2 4,506,345 $4,379,055 -$1,789,584 97.16% 42
2019 Q1 6,121,388 $8,447,399 -$8,179,669 138% 53
2018 Q4 8,624,010 $9,220,526 -$28,744,815 106.91% 63
2018 Q3 18,543,408 $114,035,615 -$22,825,928 614.97% 85
2018 Q2 20,384,198 $217,946,411 +$7,947,329 1,069.02% 83
2018 Q1 19,632,099 $210,653,586 +$82,073,345 1,072.98% 78
2017 Q4 12,323,877 $86,267,610 -$5,590,592 700% 51
2017 Q3 13,088,070 $114,093,428 -$1,666,906 873.96% 48
2017 Q2 13,285,650 $121,007,259 +$10,955,850 910.99% 51
2017 Q1 11,990,920 $95,219,588 +$3,414,277 794.02% 57
2016 Q4 11,840,741 $105,850,957 +$35,182,283 894% 59
2016 Q3 7,930,728 $137,595,118 +$10,563,413 1,735% 29
2016 Q2 7,534,407 $52,712,105 +$52,712,001 701% 16